Sanofi's sale of its consumer pharma arm, Opella, has turned into a bitter dispute. The €10 billion deal was meant to be one of Europe's biggest buyouts, but it has descended into a contentious battle between the buyer and seller. Sanofi is accusing the buyer, private equity firm Advent International, of reneging on promises made during the acquisition process. Advent has countered by claiming that Sanofi is trying to sabotage the deal through "unreasonable" demands. The dispute has raised concerns about the future of the pharmaceutical industry.

Source: https://www.bloomberg.com/news/articles/2024-10-24/how-sanofi-s-sale-of-consumer-pharma-arm-opella-turned-into-a-brawl